<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264199</url>
  </required_header>
  <id_info>
    <org_study_id>20050048</org_study_id>
    <nct_id>NCT00264199</nct_id>
  </id_info>
  <brief_title>Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure</brief_title>
  <official_title>The Effect of 48 Hours GLP-1 Infusion on Left Ventricular Function, Exercise Capacity, Insulin Sensitivity and Substrate Metabolism in Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 48 hours of glucagon-like-peptide-1 (GLP-1)
      infusion can improve heart function and alter substrate metabolism in non-diabetic patients
      with heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure is a major complication in patients with ischemic heart disease. It has been
      shown that many of these patients have areas of viable myocardium that are not effectively
      contributing to heart function.

      Further, chronic congestive heart failure is associated with some degree of insulin
      resistance in both skeletal and cardiac muscle.

      GLP-1 is a naturally occurring peptide hormone that acts as an incretin and has been
      intensively studied by many groups in association with type II diabetes and it has clearly
      shown its glucose lowering potential with very little risk of hypoglycemia in several trials.

      Recently GLP-1 has been shown to improve cardiac function in dogs with pace-induced
      cardiomyopathy, and in an open-labeled study it did improve cardiac function in patients with
      acute myocardial infarctions.

      Comparison: 48 hours of treatment with intravenous GLP-1 compared to placebo. Effect on
      global and regional left ventricular function, exercise capacity, insulin sensitivity and
      substrate metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on global left ventricular function</measure>
    <time_frame>at baseline and after 48 hours of intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on regional left ventricular function</measure>
    <time_frame>at baseline and after 48 hours of intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on exercise capacity</measure>
    <time_frame>at baseline and after 48 hours of intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on 6 minute walk test</measure>
    <time_frame>at baseline and after 48 hours of intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on insulin sensitivity</measure>
    <time_frame>after 48 hours of intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on substrate metabolism at whole-body level and in the fore-arm</measure>
    <time_frame>after 48 hours of intervention</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>iv. by weight (1.0 pmol/kg/min )</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>same rate of infusion as GLP-1</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic congestive heart failure

          -  Ischemic heart disease

        Exclusion Criteria:

          -  Diabetes

          -  Exercise limiting disease other than heart failure

          -  Congenital heart disease

          -  Arterio-venous shunts

          -  Renal failure

          -  Valvular heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Erik BÃ¸tker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Afdeling B, Skejby Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Afdeling B, Skejby Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2005</study_first_submitted>
  <study_first_submitted_qc>December 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2005</study_first_posted>
  <last_update_submitted>December 18, 2007</last_update_submitted>
  <last_update_submitted_qc>December 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2007</last_update_posted>
  <responsible_party>
    <name_title>Mads Halbirk</name_title>
    <organization>Aarhus University Hospital, Skejby</organization>
  </responsible_party>
  <keyword>Chronic Congestive heart failure</keyword>
  <keyword>Ischemic heart disease</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

